Evangelos Terpos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/63699/publications.pdf

Version: 2024-02-01

933 papers	37,245 citations	90 h-index	165 g-index
		3525	5249
943 all docs	943 docs citations	943 times ranked	27494 citing authors

#	Article	IF	Citations
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	5.1	3,343
2	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	5.1	1,866
3	Hematological findings and complications of <scp>COVID</scp>â€19. American Journal of Hematology, 2020, 95, 834-847.	2.0	1,354
4	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
5	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28, iv52-iv61.	0.6	619
6	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood, 2015, 125, 2068-2074.	0.6	586
7	International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia, 2009, 23, 1545-1556.	3.3	428
8	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncology, The, 2017, 18, e206-e217.	5.1	394
9	Soluble receptor activator of nuclear factor ÎºB ligandâ€“osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 2003, 102, 1064-1069.	0.6	386
10	The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, 2010, 115, 2354-2363.	0.6	380
11	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. Journal of Clinical Oncology, 2010, 28, 4976-4984.	0.8	358
12	Organ-specific manifestations of COVID-19 infection. Clinical and Experimental Medicine, 2020, 20, 493-506.	1.9	351
13	Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology, 2009, 20, 117-120.	0.6	347
14	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. Journal of Clinical Oncology, 2015, 33, 657-664.	0.8	330
15	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ€. Annals of Oncology, 2021, 32, 309-322.	0.6	316
16	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, 2011, 118, 4519-4529.	0.6	309
17	International Myeloma Working Group Recommendations for the Treatment of Multiple Myelomaâ€“Related Bone Disease. Journal of Clinical Oncology, 2013, 31, 2347-2357.	0.8	307
18	Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncology, The, 2018, 19, 370-381.	5.1	300

#	Article	IF	Citations
19	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology, 2016, 34, 1544-1557.	0.8	294
20	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncology, The, 2019, 20, e302-e312.	5.1	290
21	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	1.7	289
22	Primary Treatment of WaldenstrÃ¶m Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide. Journal of Clinical Oncology, 2007, 25, 3344-3349.	0.8	264
23	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia, 2017, 31, 2443-2448.	3.3	259
24	Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. British Journal of Haematology, 2006, 134, 620-623.	1.2	258
25	Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer, 2008, 113, 193-201.	2.0	243
26	Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 2020, 31, 1650-1663.	0.6	242
27	Emerging treatment strategies for COVID-19 infection. Clinical and Experimental Medicine, 2021, 21, 167-179.	1.9	232
28	Response assessment in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia: update from the <scp>VI</scp>th <scp>I</scp>nternational <scp>W</scp>orkshop. British Journal of Haematology, 2013, 160, 171-176.	1.2	226
29	Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica, 2006, 91, 968-71.	1.7	223
30	Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer Journal, 2018, 8, 7.	2.8	219
31	Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology, 2006, 135, 688-692.	1.2	217
32	Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 2012, 26, 595-608.	3.3	217
33	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia, 2016, 30, 1005-1017.	3.3	204
34	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology, 2009, 20, 1303-1317.	0.6	201
35	Myeloma bone disease: pathophysiology and management. Annals of Oncology, 2005, 16, 1223-1231.	0.6	185
36	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	1.7	185

#	Article	IF	Citations
37	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. Journal of Hematology and Oncology, 2018, 11, 10.	6.9	181
38	Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 2007, 92, 1351-1358.	1.7	179
39	Comparison of modern and conventional imaging techniques in establishing multiple myelomaâ€related bone disease: a systematic review. British Journal of Haematology, 2013, 162, 50-61.	1.2	178
40	Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia, 2009, 23, 1152-1157.	3.3	176
41	New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. British Journal of Haematology, 2004, 127, 127-139.	1.2	169
42	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	2.6	167
43	International Myeloma Working Group recommendations for global myeloma care. Leukemia, 2014, 28, 981-992.	3.3	162
44	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 801-812.	5.1	162
45	Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. International Journal of Cancer, 2006, 119, 1728-1731.	2.3	153
46	Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction postâ€bortezomib monotherapy. International Journal of Cancer, 2012, 131, 1466-1471.	2.3	150
47	Serum levels of macrophage inflammatory protein-1 alpha (MIP-1Î±) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology, 2003, 123, 106-109.	1.2	147
48	Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia, 2013, 27, 947-953.	3.3	141
49	Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 5904-5909.	0.8	139
50	Treatment recommendations for patients with WaldenstrÃ¶m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, 124, 1404-1411.	0.6	138
51	Ageâ€dependent and genderâ€dependent antibody responses against <scp>SARSâ€CoV</scp>â€2 in health workers and octogenarians after vaccination with the <scp>BNT162b2 mRNA</scp> vaccine. American Journal of Hematology, 2021, 96, E257-E259.	2.0	138
52	The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia, 2013, 27, 423-429.	3.3	137
53	Systemic IL-15, IFN-Î³, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Reports, 2021, 36, 109504.	2.9	137
54	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	5.1	136

#	Article	IF	Citations
55	VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. International Journal of Cancer, 2012, 130, 857-864.	2.3	134
56	Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. British Journal of Haematology, 2004, 126, 736-742.	1.2	131
57	Myeloma bone disease and proteasome inhibition therapies. Blood, 2007, 110, 1098-1104.	0.6	131
58	Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2013, 62, 121-126.	1.5	130
59	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood, 2021, 137, 3674-3676.	0.6	130
60	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. Journal of Infection, 2021, 83, 1-16.	1.7	127
61	VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. British Journal of Cancer, 2012, 107, 1869-1875.	2.9	126
62	Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Annals of Oncology, 2014, 25, 195-200.	0.6	126
63	Aurora kinases as targets for cancer therapy. Cancer Treatment Reviews, 2008, 34, 175-182.	3.4	124
64	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica, 2014, 99, 984-996.	1.7	124
65	Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer Journal, 2017, 7, e599-e599.	2.8	124
66	Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia, 2010, 24, 1769-1778.	3.3	120
67	The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia, 2008, 22, 2247-2256.	3.3	117
68	The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia, 2014, 28, 2402-2403.	3.3	115
69	High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. European Journal of Haematology, 2010, 85, 114-119.	1.1	113
70	The potential of proteasome inhibitors in cancer therapy. Expert Opinion on Investigational Drugs, 2008, 17, 879-895.	1.9	112
71	Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood, 2013, 121, 318-328.	0.6	112
72	Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal womenâ€"the six-month effect of risedronate and teriparatide. Osteoporosis International, 2012, 23, 1171-1176.	1.3	111

#	Article	IF	Citations
73	Advances in Imaging and the Management of Myeloma Bone Disease. Journal of Clinical Oncology, 2011, 29, 1907-1915.	0.8	110
74	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica, 2018, 103, 197-211.	1.7	110
75	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 2020, 34, 2000-2011.	3.3	109
76	Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treatment Reviews, 2008, 34, 629-639.	3.4	108
77	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of WaldenstrÃ¶m macroglobulinemia: final analysis of a phase 2 study. Blood, 2015, 126, 1392-1394.	0.6	108
78	Bone resorption is increased in young adults with thalassaemia major. British Journal of Haematology, 2001, 112, 36-41.	1.2	105
79	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. Oncologist, 2012, 17, 239-249.	1.9	105
80	Sotatercept in patients with osteolytic lesions of multiple myeloma. British Journal of Haematology, 2014, 165, 814-823.	1.2	105
81	Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends in Molecular Medicine, 2022, 28, 542-554.	3.5	104
82	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer Journal, 2021, 11, 138.	2.8	103
83	Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. British Journal of Haematology, 2002, 118, 174-180.	1.2	102
84	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Annals of Oncology, 2017, 28, 228-245.	0.6	102
85	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. Clinical Lymphoma and Myeloma, 2009, 9, 302-306.	1.4	101
86	Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplantation, 2006, 37, 731-737.	1.3	100
87	The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia, 2005, 19, 1969-1976.	3.3	99
88	Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Annals of Oncology, 2012, 23, 2681-2686.	0.6	98
89	Proteasome dysfunction inDrosophilasignals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. Aging Cell, 2013, 12, 802-813.	3.0	98
90	Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: Results from the Hellenic Dendritic Cell Leukemia Study Group. Leukemia Research, 2010, 34, 438-446.	0.4	95

#	Article	IF	Citations
91	Regulation of multiple myeloma survival and progression by CD1d. Blood, 2009, 113, 2498-2507.	0.6	94
92	Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology, 2004, 126, 686-689.	1.2	93
93	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e119-e130.	5.1	92
94	Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis. Hormone and Metabolic Research, 2009, 41, 721-729.	0.7	91
95	Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia, 2010, 24, 1043-1049.	3.3	91
96	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Advances, 2017, 1, 449-454.	2.5	89
97	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 2012, 119, 5384-5390.	0.6	88
98	Myeloma bone disease: from biology findings to treatment approaches. Blood, 2019, 133, 1534-1539.	0.6	88
99	Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia, 2001, 15, 1369-1376.	3.3	86
100	Management of bone disease in multiple myeloma. Expert Review of Hematology, 2014, 7, 113-125.	1.0	86
101	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	1.7	86
102	Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treatment Reviews, 2019, 76, 57-67.	3.4	85
103	Tartrate-resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma. International Journal of Cancer, 2003, 106, 455-457.	2.3	84
104	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	2.0	84
105	Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factorâ€“ÎºB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta OncolÃ³gica, 2007, 46, 221-229.	0.8	83
106	The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia, 2007, 21, 1875-1884.	3.3	83
107	Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFÎ± in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecologic Oncology, 2008, 108, 421-427.	0.6	83
108	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia, 2018, 32, 1697-1712.	3.3	83

#	Article	IF	Citations
109	Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood, 2019, 133, 710-723.	0.6	82
110	Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. British Journal of Haematology, 2003, 123, 730-737.	1.2	81
111	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. American Journal of Hematology, 2012, 87, 861-864.	2.0	81
112	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. Radiology, 2017, 282, 484-493.	3.6	81
113	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	3.3	81
114	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	3.3	79
115	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalanâ€“prednisone vs. melphalanâ€“prednisone in the phase III VISTA trial in multiple myeloma. European Journal of Haematology, 2011, 86, 372-384.	1.1	77
116	The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia, 2010, 24, 1700-1712.	3.3	76
117	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leukemia and Lymphoma, 2008, 49, 890-895.	0.6	74
118	Multiple myeloma. Annals of Oncology, 2010, 21, vii143-vii150.	0.6	73
119	Bortezomibâ€based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. American Journal of Hematology, 2016, 91, 499-502.	2.0	73
120	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica, 2017, 102, 593-599.	1.7	72
121	Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia, 2003, 17, 89-97.	3.3	71
122	Cardiovascular adverse events in modern myeloma therapy â€“ Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica, 2018, 103, 1422-1432.	1.7	70
123	Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Annals of Oncology, 2003, 14, 1039-1044.	0.6	69
124	Increased bone resorption is implicated in the pathogenesis of bone loss in hemophiliacs: correlations with hemophilic arthropathy and HIV infection. Annals of Hematology, 2010, 89, 67-74.	0.8	68
125	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	3.3	68
126	Prevalence and significance of vitamin D deficiency in multiple myeloma patients. British Journal of Haematology, 2008, 142, 492-494.	1.2	67

#	Article	IF	Citations
127	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	3.4	67
128	Early markers of renal dysfunction in patients with sickle cell/Î²-thalassemia. Kidney International, 2006, 69, 2037-2042.	2.6	66
129	Sickleâ€cell disease and the heart: review of the current literature. British Journal of Haematology, 2012, 157, 664-673.	1.2	65
130	Significance of macrophage inflammatory protein-1 alpha (MIP-1Î±) in multiple myeloma. Leukemia and Lymphoma, 2005, 46, 1699-1707.	0.6	64
131	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leukemia Research, 2010, 34, 1395-1397.	0.4	64
132	Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease. Clinical Cancer Research, 2014, 20, 5888-5897.	3.2	64
133	Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. European Journal of Haematology, 2000, 65, 331-336.	1.1	63
134	Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplantation, 2003, 31, 163-170.	1.3	62
135	Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opinion on Therapeutic Targets, 2009, 13, 839-848.	1.5	62
136	Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia, 2010, 24, 1206-1212.	3.3	62
137	Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia, 2004, 18, 1420-1426.	3.3	61
138	Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. European Journal of Haematology, 2005, 75, 376-383.	1.1	61
139	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e401-e419.	0.2	61
140	Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica, 2009, 94, 372-379.	1.7	60
141	CCL3 Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1231, 13-21.	0.8	60
142	VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Annals of Oncology, 2007, 18, 1369-1375.	0.6	59
143	Treatment options for thalassemia patients with osteoporosis. Annals of the New York Academy of Sciences, 2010, 1202, 237-243.	1.8	59
144	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer Journal, 2018, 8, 95.	2.8	59

#	Article	IF	Citations
145	Pulmonary hypertension in patients with sickle cell/Â thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica, 2007, 92, 738-743.	1.7	58
146	Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opinion on Investigational Drugs, 2013, 22, 87-101.	1.9	58
147	High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-Î¹B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clinical Biochemistry, 2008, 41, 746-749.	0.8	57
148	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leukemia and Lymphoma, 2014, 55, 2018-2023.	0.6	57
149	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia, 2014, 28, 2075-2079.	3.3	57
150	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leukemia Research, 2010, 34, 1340-1343.	0.4	56
151	Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Annals of Oncology, 2010, 21, 1561-1562.	0.6	56
152	Treatment with bortezomibâ€based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. American Journal of Hematology, 2014, 89, 145-150.	2.0	56
153	Reâ€evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Hematological Oncology, 2013, 31, 96-102.	0.8	55
154	Longâ€term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. American Journal of Hematology, 2015, 90, E60-5.	2.0	55
155	Increased expression of macrophage inflammatory protein-1Î± on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia, 2009, 23, 2177-2181.	3.3	54
156	High Circulating Sclerostin is Present in Patients with Thalassemia-associated Osteoporosis and Correlates with Bone Mineral Density. Hormone and Metabolic Research, 2012, 44, 909-913.	0.7	54
157	Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients. American Journal of Hematology, 2014, 89, 803-808.	2.0	54
158	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood, 2018, 131, 464-467.	0.6	54
159	A revised international prognostic score system for WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia, 2019, 33, 2654-2661.	3.3	53
160	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer Journal, 2019, 9, 27.	2.8	53
161	SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. European Journal of Internal Medicine, 2021, 89, 87-96.	1.0	53
162	The effect of teriparatide on serum Dickkopfâ€1 levels in postmenopausal women with established osteoporosis. Clinical Endocrinology, 2010, 72, 752-757.	1.2	52

#	Article	IF	Citations
163	The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer, 2014, 120, 618-623.	2.0	52
164	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naÃ¯ve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208.	2.3	52
165	Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica, 2006, 91, 1193-202.	1.7	51
166	Hereditary Hemochromatosis: HFE Mutation Analysis in Greeks Reveals Genetic Heterogeneity. Blood Cells, Molecules, and Diseases, 2000, 26, 163-168.	0.6	50
167	Biology and treatment of myeloma related bone disease. Metabolism: Clinical and Experimental, 2018, 80, 80-90.	1.5	49
168	Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: Implications for multiple myeloma. European Journal of Immunology, 2011, 41, 437-449.	1.6	48
169	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. American Journal of Hematology, 2017, 92, 632-639.	2.0	48
170	Role of the RANK/RANKL Pathway in Multiple Myeloma. Clinical Cancer Research, 2019, 25, 12-20.	3.2	48
171	Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. Cancers, 2020, 12, 191.	1.7	48
172	Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2011, 29, 921-5.	0.4	48
173	New insights into the pathophysiology and management of bone disease in multiple myeloma. British Journal of Haematology, 2003, 123, 758-769.	1.2	47
174	Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica, 2009, 94, 725-728.	1.7	46
175	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. Journal of Oncology, 2020, 2020, 1-11.	0.6	46
176	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 2021, 11, 40.	2.8	46
177	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	2.2	46
178	Pathogenesis and management of myeloma bone disease. Expert Review of Hematology, 2009, 2, 385-398.	1.0	45
179	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 2021, 5, e528.	1.2	45
180	Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and Î²2 -microglobulin in multiple myeloma. European Journal of Haematology, 2003, 70, 34-42.	1.1	44

#	Article	IF	Citations
181	Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated IÎºB kinase. Journal of Cancer Research and Clinical Oncology, 2009, 135, 173-179.	1.2	44
182	Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stemâ€cell transplantation: Results of a single institution, randomized phase 2 trial. American Journal of Hematology, 2010, 85, 863-867.	2.0	44
183	Impact of bortezomib on bone health in myeloma: A review of current evidence. Cancer Treatment Reviews, 2012, 38, 968-980.	3.4	44
184	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica, 2015, 100, e446-e449.	1.7	44
185	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood, 2018, 131, 1568-1575.	0.6	44
186	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers, 2021, 13, 4480.	1.7	44
187	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematology,the, 2022, 9, e143-e161.	2.2	44
188	No significant improvement in the outcome of patients with WaldenstrÃ¶m's macroglobulinemia treated over the last 25 years. American Journal of Hematology, 2011, 86, 479-483.	2.0	43
189	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Annals of Hematology, 2015, 94, 2033-2042.	0.8	43
190	Bone health in the elderly cancer patient: A SIOG position paper. Cancer Treatment Reviews, 2016, 51, 46-53.	3.4	43
191	Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer Journal, 2016, 6, e378-e378.	2.8	43
192	PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia, 2016, 30, 238-242.	3.3	43
193	Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. Journal of Cancer Research and Clinical Oncology, 2004, 130, 623-5.	1.2	42
194	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. Journal of Internal Medicine, 2019, 286, 63-74.	2.7	42
195	Multiple myeloma: Role of autologous transplantation. Cancer Treatment Reviews, 2020, 82, 101929.	3.4	42
196	The Emerging Role of Convalescent Plasma in the Treatment of COVIDâ€19. HemaSphere, 2020, 4, e409.	1.2	42
197	The role of markers of bone remodeling in multiple myeloma. Blood Reviews, 2005, 19, 125-142.	2.8	41
198	The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e407-e417.	1.8	41

#	Article	IF	Citations
199	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. Journal of Medicinal Chemistry, 2016, 59, 8787-8803.	2.9	41
200	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomideâ€based regimens. American Journal of Hematology, 2013, 88, 765-770.	2.0	40
201	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia, 2018, 32, 2617-2625.	3.3	40
202	Clinical implications of chromosomal abnormalities in multiple myeloma. Leukemia and Lymphoma, 2006, 47, 803-814.	0.6	39
203	Increased Serum Lactate Dehydrongenase Should Be Included Among the Variables That Define Very-High-Risk Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 409-413.	0.2	39
204	Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after singleâ€agent chelation therapies. British Journal of Haematology, 2011, 154, 654-656.	1.2	39
205	Phase 2 study of tabalumab, a human antiâ€Bâ€cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. British Journal of Haematology, 2017, 176, 783-795.	1.2	39
206	Mechanisms of bone destruction in multiple myeloma. European Journal of Cancer Care, 2017, 26, e12761.	0.7	39
207	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer Journal, 2018, 8, 46.	2.8	39
208	Antiâ€“SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Microorganisms, 2020, 8, 1885.	1.6	39
209	The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 4462.	1.8	39
210	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. Blood Advances, 2021, 5, 4398-4405.	2.5	39
211	Biochemical markers of bone metabolism in multiple myeloma. Cancer Treatment Reviews, 2006, 32, 15-19.	3.4	38
212	Novel anti-myeloma agents and angiogenesis. Leukemia and Lymphoma, 2008, 49, 677-689.	0.6	38
213	â€œReal-worldâ€•data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Annals of Hematology, 2014, 93, 129-139.	0.8	38
214	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. Thrombosis and Haemostasis, 2020, 120, 1680-1690.	1.8	38
215	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells, 2021, 10, 1942.	1.8	38
216	Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica, 2006, 91, 252-4.	1.7	38

#	Article	IF	Citations
217	Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. British Journal of Haematology, 2007, 137, 560-568.	1.2	37
218	Hyperphosphorylated pararg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and WaldenstrÃ¶m macroglobulinemia. Blood, 2011, 117, 2918-2923.	0.6	37
219	The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC. European Journal of Haematology, 2013, 91, n/a-n/a.	1.1	37
220	Optimal use of bisphosphonates in patients with multiple myeloma. Blood, 2013, 121, 3325-3328.	0.6	37
221	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. European Journal of Haematology, 2017, 99, 409-414.	1.1	37
222	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Advances, 2019, 3, 3002-3009.	2.5	37
223	Deferiprone as an oral iron chelator in sickle cell disease. Annals of Hematology, 2005, 84, 434-440.	0.8	36
224	A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty. British Journal of Haematology, 2010, 151, 359-364.	1.2	36
225	Lateâ€onset hematological complications post <scp>COVID</scp>â€19: An emerging medical problem for the hematologist. American Journal of Hematology, 2022, 97, 119-128.	2.0	36
226	Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma. American Journal of Hematology, 2008, 83, 697-701.	2.0	35
227	Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leukemia Research, 2008, 32, 1153-1156.	0.4	35
228	Prognostic Significance of Bone Markers in Patients With Lung Cancer Metastatic to the Skeleton: A Review of Published Data. Clinical Lung Cancer, 2011, 12, 341-349.	1.1	35
229	Clinical vertebral fractures following denosumab discontinuation. Endocrine, 2016, 54, 271-272.	1.1	35
230	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer Journal, 2018, 8, 31.	2.8	35
231	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Frontiers in Oncology, 2020, 10, 860.	1.3	35
232	Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic featuresâ€"An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2013, 2, 70-76.	1.0	34
233	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Review of Hematology, 2020, 13, 421-433.	1.0	34
234	Immunogenic Cell Death, DAMPs and Prothymosin Î± as a Putative Anticancer Immune Response Biomarker. Cells, 2022, 11, 1415.	1.8	34

#	Article	IF	Citations
235	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. American Journal of Hematology, 2014, 89, 34-40.	2.0	33
236	Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer Journal, 2017, 7, e571-e571.	2.8	33
237	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. Scientific Reports, 2021, 11, 6614.	1.6	33
238	Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis. Haematologica, 2006, 91, 813-6.	1.7	33
239	Circulating angiopoietinâ€1 to angiopoietinâ€2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. International Journal of Cancer, 2012, 130, 735-742.	2.3	32
240	VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia, 2014, 28, 928-934.	3.3	32
241	Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders. Haematologia, 2001, 31, 7-16.	0.2	31
242	Treatment with deferasirox (Exjade^{Â®}) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. British Journal of Haematology, 2010, 148, 332-334.	1.2	31
243	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica, 2011, 96, 1557-1559.	1.7	31
244	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. European Journal of Haematology, 2014, 92, 308-312.	1.1	31
245	Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. Blood Cancer Journal, 2017, 7, e570-e570.	2.8	31
246	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life, 2020, 10, 214.	1.1	31
247	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of Hematology, 2020, 99, 1049-1061.	0.8	31
248	SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. HemaSphere, 2021, 5, e547.	1.2	31
249	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. Journal of Hematology and Oncology, 2021, 14, 86.	6.9	31
250	The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e407-e417.	1.8	31
251	Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis. Leukemia and Lymphoma, 2006, 47, 1553-1556.	0.6	30
252	RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opinion on Investigational Drugs, 2009, 18, 1085-1102.	1.9	30

#	Article	IF	Citations
253	Sclerostin: a possible target for the management of cancer-induced bone disease. Expert Opinion on Therapeutic Targets, 2012, 16, 761-769.	1.5	30
254	Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. Haematologica, 2012, 97, 1699-1703.	1.7	30
255	Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. OncoTargets and Therapy, 2013, 6, 531.	1.0	30
256	Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treatment Reviews, 2015, 41, 827-835.	3.4	30
257	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clinical and Experimental Medicine, 2022, 22, 319-323.	1.9	30
258	Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Annals of Hematology, 2007, 86, 369-376.	0.8	29
259	RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opinion on Biological Therapy, 2009, 9, 465-479.	1.4	29
260	Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Medical Oncology, 2010, 27, 332-338.	1.2	29
261	DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. Blood, 2016, 128, 1214-1225.	0.6	29
262	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 329-339.	0.2	29
263	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer Journal, 2018, 8, 42.	2.8	29
264	The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Research, 2009, 29, 1651-7.	0.5	29
265	Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma. Acta Haematologica, 2005, 114, 170-173.	0.7	28
266	Renal Insufficiency and Failure. Hematology American Society of Hematology Education Program, 2010, 2010, 431-436.	0.9	28
267	Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leukemia and Lymphoma, 2011, 52, 2299-2303.	0.6	28
268	The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patientsâ€™ renal function. Annals of Oncology, 2012, 23, 722-729.	0.6	28
269	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. European Journal of Haematology, 2012, 89, 10-15.	1.1	28
270	Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point. Haematologica, 2015, 100, e328-30.	1.7	28

#	Article	IF	Citations
271	Current treatments for renal failure due to multiple myeloma. Expert Opinion on Pharmacotherapy, 2016, 17, 2165-2177.	0.9	28
272	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. Expert Review of Hematology, 2018, 11, 219-237.	1.0	28
273	Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica, 2009, 94, 725-728.	1.7	28
274	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood, 2022, 139, 1409-1412.	0.6	28
275	The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematological Oncology, 2004, 22, 159-168.	0.8	27
276	Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica, 2008, 93, 1588-1590.	1.7	27
277	Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica, 2008, 93, 451-454.	1.7	27
278	Current treatments for renal failure due to multiple myeloma. Expert Opinion on Pharmacotherapy, 2013, 14, 1477-1495.	0.9	27
279	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. Haematologica, 2021, 106, 2054-2065.	1.7	27
280	Bortezomib is an effective agent for MDS/MPD syndrome with 5qâ^' anomaly and thrombocytosis. Leukemia Research, 2007, 31, 559-562.	0.4	26
281	Management of Complications in Multiple Myeloma. Seminars in Hematology, 2009, 46, 176-189.	1.8	26
282	Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Pagetâ€™s disease. Journal of Bone and Mineral Metabolism, 2010, 28, 706-712.	1.3	26
283	High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leukemia Research, 2010, 34, 399-402.	0.4	26
284	Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. Cancer Immunology, Immunotherapy, 2011, 60, 305-317.	2.0	26
285	Pregnancy in betaâ€thalassemia intermedia: 20â€year experience of a Greek thalassemia center. European Journal of Haematology, 2014, 93, 492-499.	1.1	26
286	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses, 2021, 13, 26.	1.5	26
287	Circulating Periostin Levels do not Differ Between Postmenopausal Women with Normal and Low Bone Mass and are not Affected by Zoledronic Acid Treatment. Hormone and Metabolic Research, 2014, 46, 145-149.	0.7	25
288	Emerging antibodies for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2016, 21, 225-237.	1.0	25

#	Article	IF	Citations
289	Cost of skeletal complications from bone metastases in six European countries. Journal of Medical Economics, 2016, 19, 611-618.	1.0	25
290	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines, 2021, 9, 712.	2.1	25
291	BCMA in Multiple Myelomaâ€"A Promising Key to Therapy. Journal of Clinical Medicine, 2021, 10, 4088.	1.0	25
292	Bisphosphonate treatment for multiple myeloma. Drugs of Today, 2004, 40, 29.	2.4	25
293	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. Life, 2021, 11, 1077.	1.1	25
294	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 793953.	2.2	25
295	Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, 346-353.	1.4	24
296	The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL in Patients with Paget's Disease of Bone. Hormone and Metabolic Research, 2009, 41, 846-850.	0.7	24
297	Serum Levels of Total-RANKL in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2009, 9, 430-435.	1.4	24
298	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. Journal of Bone and Mineral Metabolism, 2016, 34, 447-456.	1.3	24
299	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leukemia and Lymphoma, 2017, 58, 1832-1839.	0.6	24
300	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 234-241.	1.4	24
301	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. Cancers, 2020, 12, 3245.	1.7	24
302	Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia. British Journal of Haematology, 2006, 133, 301-304.	1.2	23
303	Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Critical Reviews in Oncology/Hematology, 2011, 77, S13-S23.	2.0	23
304	Tobacco smoking and risk of multiple myeloma: A metaâ€analysis of 40 observational studies. International Journal of Cancer, 2013, 132, 2413-2431.	2.3	23
305	An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2017, 18, 1883-1897.	0.9	23
306	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer Journal, 2018, 8, 102.	2.8	23

#	Article	IF	Citations
307	INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncology, 2019, 15, 1411-1428.	1.1	23
308	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 445-452.	0.2	23
309	Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: A case report and review of the literature. American Journal of Hematology, 2001, 66, 57-58.	2.0	22
310	Bortezomib in multiple myeloma. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 639-654.	1.5	22
311	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. Circulation Research, 2019, 125, 744-758.	2.0	22
312	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 19-23.	1.4	22
313	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	1.7	22
314	SjÃ¶gren's syndrome associated with multiple myeloma. Annals of Hematology, 2000, 79, 449-451.	0.8	21
315	Detection of CD55- and/or CD59-Deficient Red Cell Populations in Patients With Plasma Cell Dyscrasias. International Journal of Hematology, 2002, 75, 40-44.	0.7	21
316	Hemodynamic Markers and Subclinical Atherosclerosis in Postmenopausal Women With Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2704-2711.	1.8	21
317	A review of the venous thrombotic issues associated with multiple myeloma. Expert Review of Hematology, 2016, 9, 695-706.	1.0	21
318	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. American Journal of Hematology, 2019, 94, 400-407.	2.0	21
319	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. Blood Cancer Journal, 2020, 10, 109.	2.8	21
320	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology, 2021, 100, 2325-2337.	0.8	21
321	Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes. The Hematology Journal, 2001, 2, 33-37.	2.0	21
322	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. Biomedicines, 2022, 10, 338.	1.4	21
323	Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment. Calcified Tissue International, 2001, 68, 285-290.	1.5	20
324	Acute myeloid leukemia in a patient with ataxia-telangiectasia: a case report and review of the literature. Leukemia, 2001, 15, 1668-1670.	3.3	20

#	Article	IF	Citations
325	Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients. International Journal of Dentistry, 2014, 2014, 1-7.	0.5	20
326	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. HemaSphere, 2019, 3, e300.	1.2	20
327	Myelodysplastic features in patients with long-term HIV infection and haemophilia. Haemophilia, 2001, 7, 47-52.	1.0	20
328	Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece. Medicine (United States), 2020, 99, e23845.	0.4	20
329	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	20
330	Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. European Journal of Haematology, 2005, 74, 359-361.	1.1	19
331	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leukemia and Lymphoma, 2015, 56, 1723-1726.	0.6	19
332	Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. Blood Cancer Journal, 2016, 6, e428-e428.	2.8	19
333	Anti-BCMA antibodies in the future management of multiple myeloma. Expert Review of Anticancer Therapy, 2019, 19, 319-326.	1.1	19
334	Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. Blood Advances, 2021, 5, 725-736.	2.5	19
335	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Advances, 2022, 6, 690-703.	2.5	19
336	Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma â‰¥ 75 Years of Age.. Blood, 2004, 104, 1482-1482.	0.6	19
337	Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria. Medical Science Monitor, 2003, 9, RA161-72.	0.5	19
338	Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response. American Journal of Hematology, 2009, 84, 524-526.	2.0	18
339	Effects of proteasome inhibitors on bone cancer. BoneKEy Reports, 2013, 2, 395.	2.7	18
340	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 3-11.	1.4	18
341	Myeloma patients with COVIDâ€19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. British Journal of Haematology, 2022, 196, 356-359.	1.2	18
342	IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents. Blood, 2013, 122, 1935-1935.	0.6	18

#	Article	IF	Citations
343	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. Radiology, 2022, 304, 137-144.	3.6	18
344	Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. British Journal of Haematology, 2008, 142, 3-10.	1.2	17
345	Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Pagetâ€™s disease of bone. Osteoporosis International, 2011, 22, 363-367.	1.3	17
346	Tumorâ€primed natural killer cells from patients with multiple myeloma lyse autologous, NKâ€resistant, bone marrowâ€derived malignant plasma cells. American Journal of Hematology, 2011, 86, 967-973.	2.0	17
347	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leukemia and Lymphoma, 2017, 58, 2304-2309.	0.6	17
348	Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Scientific Reports, 2017, 7, 17802.	1.6	17
349	A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Journal of Medical Economics, 2018, 21, 525-536.	1.0	17
350	The role of sclerostin/dickkopfâ€1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A crossâ€sectional study. Haemophilia, 2018, 24, 316-322.	1.0	17
351	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Annals of Hematology, 2018, 97, 1671-1682.	0.8	17
352	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Advances, 2019, 3, 4095-4103.	2.5	17
353	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Annals of Hematology, 2020, 99, 1251-1255.	0.8	17
354	Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. International Journal of Molecular Sciences, 2021, 22, 2375.	1.8	17
355	Comparison of neutralizing antibody responses against <scp>SARSâ€CoV</scp>â€2 in healthy volunteers who received the <scp>BNT162b2 mRNA</scp> or the <scp>AZD1222</scp> vaccine: Should the second <scp>AZD1222</scp> vaccine dose be given earlier?. American Journal of Hematology, 2021, 96, E321-E324.	2.0	17
356	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. HemaSphere, 2022, 6, e677.	1.2	17
357	Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination. JAMA Oncology, 2022, 8, 201.	3.4	17
358	Inflammatory pseudotumor of the spleen: a case report and review of the literature. Annals of Hematology, 1999, 78, 560-563.	0.8	16
359	Leukemogenic Risk of Hydroxyurea Therapy as a Single Agent in Polycythemia Vera and Essential Thrombocythemia: N-and K-ras Mutations and Microsatellite Instability in Chromosomes 5 and 7 in 69 Patients. International Journal of Hematology, 2002, 75, 394-400.	0.7	16
360	Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin. Clinical Microbiology and Infection, 2003, 9, 1238-1241.	2.8	16

#	Article	IF	Citations
361	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. American Journal of Hematology, 2011, 86, 882-884.	2.0	16
362	Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. Cancer Treatment Reviews, 2012, 38, 1012-1019.	3.4	16
363	A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. Biomarkers, 2013, 18, 607-613.	0.9	16
364	Correlation of Fc-Î³ RIIA polymorphisms with latent Epsteinâ€“Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas. Leukemia and Lymphoma, 2013, 54, 2030-2034.	0.6	16
365	Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 335-340.	0.2	16
366	High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. Blood Cancer Journal, 2016, 6, e482-e482.	2.8	16
367	Neutrophil Gelatinaseâ€“Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 29-35.	0.2	16
368	Health resource utilization associated with skeletal-related events: results from a retrospective European study. European Journal of Health Economics, 2016, 17, 711-721.	1.4	16
369	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting,Â2017. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 321-334.	0.2	16
370	Bortezomib retreatment for relapsed and refractory multiple myeloma in realâ€world clinical practice. Health Science Reports, 2019, 2, e104.	0.6	16
371	The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/Î²thal), correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hypertension. Blood Cells, Molecules, and Diseases, 2019, 77, 137-141.	0.6	16
372	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. Blood Cancer Journal, 2020, 10, 25.	2.8	16
373	Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19. Diagnostics, 2021, 11, 995.	1.3	16
374	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). Blood, 2016, 128, 3307-3307.	0.6	16
375	How I treat relapsed multiple myeloma. Blood, 2022, 139, 2904-2917.	0.6	16
376	Successful Treatment of Extramedullary Plasmacytoma of the Carvenous Sinus Using a Combination of Intermediate Dose of Thalidomide and Dexamethasone. Acta Haematologica, 2007, 117, 20-23.	0.7	15
377	Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert Opinion on Biological Therapy, 2009, 9, 207-220.	1.4	15
378	Pagetâ€™s Disease of Bone and Calcium Homeostasis: Focus on Bisphosphonate Treatment. Experimental and Clinical Endocrinology and Diabetes, 2011, 119, 519-524.	0.6	15

#	Article	IF	Citations
379	Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2012, 58, 819-822.	0.8	15
380	Baseline osteocalcin levels and incident diabetes in a 3-year prospective study of high-risk individuals. Diabetes and Metabolism, 2014, 40, 198-203.	1.4	15
381	Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. Blood Cancer Journal, 2015, 5, e319-e319.	2.8	15
382	Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. BoneKEy Reports, 2015, 4, 744.	2.7	15
383	Bortezomibâ€based therapy for relapsed/refractory multiple myeloma in realâ€world medical practice. European Journal of Haematology, 2018, 101, 556-565.	1.1	15
384	Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. Annals of Hematology, 2019, 98, 1457-1466.	0.8	15
385	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. Cancers, 2020, 12, 2006.	1.7	15
386	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer Journal, 2020, 10, 40.	2.8	15
387	Daratumumabâ€based therapy for patients with monoclonal gammopathy of renal significance. British Journal of Haematology, 2021, 193, 113-118.	1.2	15
388	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia, 2021, 35, 1418-1427.	3.3	15
389	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. Oncologist, 2021, 26, 597-609.	1.9	15
390	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. Breast, 2021, 60, 58-61.	0.9	15
391	Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection. Medical Science Monitor, 2008, 14, CR276-280.	0.5	15
392	Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study. Frontiers in Endocrinology, 2022, 13, 840668.	1.5	15
393	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leukemia and Lymphoma, 2010, 51, 2006-2011.	0.6	14
394	Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Advances, 2018, 2, 2837-2847.	2.5	14
395	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. HemaSphere, 2020, 4, e381.	1.2	14
396	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms, 2021, 9, 546.	1.6	14

#	Article	IF	Citations
397	Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. Cells, 2022, 11, 1241.	1.8	14
398	Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. British Journal of Haematology, 2002, 116, 155-157.	1.2	13
399	Continuous Increase in Erythropoietic Activity despite the Improvement in Bone Mineral Density by Zoledronic Acid in Patients with Thalassemia Intermedia-Induced Osteoporosis. Acta Haematologica, 2008, 119, 40-44.	0.7	13
400	Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Supportive Care in Cancer, 2009, 17, 1329-1330.	1.0	13
401	Alcohol intake, alcoholic beverage type and multiple myeloma risk: a meta-analysis of 26 observational studies. Leukemia and Lymphoma, 2015, 56, 1484-1501.	0.6	13
402	Emerging treatment approaches for myeloma-related bone disease. Expert Review of Hematology, 2017, 10, 217-228.	1.0	13
403	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual MeetingÂ2018. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e324-e336.	0.2	13
404	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer Journal, 2020, 10, 93.	2.8	13
405	Controversies in the use of new boneâ€modifying therapies in multiple myeloma. British Journal of Haematology, 2021, 193, 1034-1043.	1.2	13
406	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.. Blood, 2005, 106, 363-363.	0.6	13
407	High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.. Blood, 2009, 114, 425-425.	0.6	13
408	DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).. Journal of Clinical Oncology, 2020, 38, TPS8556-TPS8556.	0.8	13
409	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 13144.	1.8	13
410	Detection of â€œPNH Red Cellâ€•Populations in Hematological Disorders Using the Sephacryl Gel Test Micro Typing System. Leukemia and Lymphoma, 1997, 28, 177-182.	0.6	12
411	Red Cells with Paroxysmal Nocturnal Hemoglobinuria-phenotype in Patients with Acute Leukemia. Hematology, 2002, 7, 69-74.	0.7	12
412	Angiogenesis in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 46-49.	1.4	12
413	Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. Osteoporosis International, 2013, 24, 2127-2132.	1.3	12
414	Effects of singleâ€agent bortezomib as postâ€transplant consolidation therapy on multiple myelomaâ€related bone disease: a randomized phase <scp>II</scp> study. British Journal of Haematology, 2017, 178, 61-71.	1.2	12

#	Article	IF	Citations
415	Current treatment options and investigational drugs for Waldenstromâ€™s Macroglobulinemia. Expert Opinion on Investigational Drugs, 2017, 26, 197-205.	1.9	12
416	Variation of endotheliumâ€related hemostatic factors during sepsis. Microcirculation, 2018, 25, e12500.	1.0	12
417	Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?. Expert Review of Hematology, 2019, 12, 651-663.	1.0	12
418	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Cancers, 2020, 12, 2864.	1.7	12
419	Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection . OncoTargets and Therapy, 2020, Volume 13, 6405-6416.	1.0	12
420	Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. International Journal of Molecular Sciences, 2020, 21, 5185.	1.8	12
421	Cellâ€free <scp>DNA</scp> analysis for the detection of <scp>MYD88</scp> and <scp>CXCR4</scp> mutations in <scp>IgM</scp> monoclonal gammopathies; an update with clinicopathological correlations. American Journal of Hematology, 2020, 95, E148-E150.	2.0	12
422	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines, 2021, 9, 207.	2.1	12
423	A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. Microorganisms, 2021, 9, 806.	1.6	12
424	Covidâ€19 vaccination in patients with multiple myeloma: Focus on immune response. American Journal of Hematology, 2021, 96, 896-900.	2.0	12
425	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. Cancers, 2021, 13, 3877.	1.7	12
426	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. PLoS Pathogens, 2021, 17, e1009701.	2.1	12
427	Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. Blood, 2019, 134, 1887-1887.	0.6	12
428	Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics. Blood, 2019, 134, 606-606.	0.6	12
429	Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption,. Blood, 2011, 118, 3922-3922.	0.6	12
430	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study. Blood, 2012, 120, 438-438.	0.6	12
431	Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. Blood, 2015, 126, 4178-4178.	0.6	12
432	The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon. Medical Science Monitor, 2014, 20, 123-139.	0.5	12

#	Article	IF	Citations
433	Distinct neutralization profile of spike variants by antibodies induced upon <scp>SARSâ€CoV</scp>â€2 infection or vaccination. American Journal of Hematology, 2022, 97, E3.	2.0	12
434	Current treatment options for myeloma. Expert Opinion on Pharmacotherapy, 2005, 6, 1127-1142.	0.9	11
435	High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. British Journal of Haematology, 2010, 150, 587-591.	1.2	11
436	Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell Histiocytosis?. Molecular Therapy, 2012, 20, 6-7.	3.7	11
437	Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy. Leukemia and Lymphoma, 2012, 53, 1057-1061.	0.6	11
438	Prevention and Treatment of Myeloma Bone Disease. Current Hematologic Malignancy Reports, 2012, 7, 249-257.	1.2	11
439	Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis. Leukemia, 2014, 28, 1113-1121.	3.3	11
440	Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. Leukemia, 2017, , .	3.3	11
441	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leukemia and Lymphoma, 2019, 60, 163-171.	0.6	11
442	Updates on thrombotic events associated with multiple myeloma. Expert Review of Hematology, 2019, 12, 355-365.	1.0	11
443	Bone marrow biopsy in lowâ€risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. American Journal of Hematology, 2019, 94, E146-E149.	2.0	11
444	Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 499-508.	0.2	11
445	A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1487-1497.	3.3	11
446	Real-World Treatment of Patients With Relapsed/Refractory Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 379-385.	0.2	11
447	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology, 2021, 17, 2499-2512.	1.1	11
448	Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group. Blood, 2016, 128, 4468-4468.	0.6	11
449	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. British Journal of Cancer, 2022, 126, 79-90.	2.9	11
450	Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Annals of Hepatology, 2013, 12, 749-57.	0.6	11

#	Article	IF	Citations
451	Effect of Strontium Ranelate on Lumbar Spine Bone Mineral Density in Women with Established Osteoporosis Previously Treated with Teriparatide. Hormone and Metabolic Research, 2009, 41, 559-562.	0.7	10
452	Pagetâ€™s disease of bone: emphasis on treatment with zoledronic acid. Expert Review of Endocrinology and Metabolism, 2009, 4, 423-434.	1.2	10
453	Incorporating novel agents in the treatment of myelodysplastic syndromes. Leukemia Research, 2010, 34, 6-17.	0.4	10
454	Lenalidomide: an update on evidence from clinical trials. Blood Reviews, 2010, 24, S21-S26.	2.8	10
455	Expression of CCL3 by Neoplastic Cells in Patients with WaldenstrÃ¶m's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 115-117.	0.2	10
456	Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E618-E621.	1.8	10
457	Is it possible to cure myeloma without allogeneic transplantation?. Transfusion and Apheresis Science, 2016, 54, 63-70.	0.5	10
458	Primary failure of bortezomib in newly diagnosed multiple myeloma â€“ understanding the magnitude, predictors, and significance. Leukemia and Lymphoma, 2016, 57, 1382-1388.	0.6	10
459	Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Review of Hematology, 2018, 11, 881-888.	1.0	10
460	Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2019, 25, 2-10.	1.0	10
461	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. International Journal of Cancer, 2019, 145, 559-568.	2.3	10
462	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 57-62.	0.2	10
463	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. Annals of Hematology, 2021, 100, 2279-2292.	0.8	10
464	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 361-367.	0.2	10
465	Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. Journal of Clinical Medicine, 2021, 10, 3940.	1.0	10
466	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. Journal of Clinical Medicine, 2021, 10, 4179.	1.0	10
467	Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. Oncotarget, 2018, 9, 17797-17809.	0.8	10
468	The extended 4-year follow-up results of the ELOQUENT-2 trial. Oncotarget, 2019, 10, 82-83.	0.8	10

#	Article	IF	Citations
469	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. Vaccines, 2021, 9, 1148.	2.1	10
470	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. Frontiers in Immunology, 2021, 12, 746203.	2.2	10
471	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. Blood Advances, 2022, 6, 189-199.	2.5	10
472	Third dose of the <scp>BNT162b2</scp> vaccine results in very high levels of neutralizing antibodies against <scp>SARSâ€CoV</scp>â€2: Results of a prospective study in 150 health professionals in Greece. American Journal of Hematology, 2022, 97, .	2.0	10
473	Chromosome 1q21 aberrations identify ultra <scp>highâ€risk</scp> myeloma with prognostic and clinical implications. American Journal of Hematology, 2022, 97, 1142-1149.	2.0	10
474	Unusual Association between Increased Bone Resorption and Presence of Paroxysmal Nocturnal Hemoglobinuria Phenotype in Multiple Myeloma. International Journal of Hematology, 2003, 78, 344-348.	0.7	9
475	Autoimmune Hemolytic Anemia with Myelodysplastic Features Followed by Bilateral Adrenal Non-Hodgkin Lymphoma: A Case Report and Review of the Literature. Leukemia and Lymphoma, 2004, 45, 2333-2338.	0.6	9
476	Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma. Cancer Treatment Reviews, 2009, 35, 738-743.	3.4	9
477	Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/Î²-thalassemia. Annals of Hematology, 2011, 90, 11-15.	0.8	9
478	An update on the use of lenalidomide for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2015, 16, 1865-1877.	0.9	9
479	Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma. Blood Cancer Journal, 2016, 6, e500-e500.	2.8	9
480	An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomideâ€‰+â€‰dexamethasone for relapsed or relapsed/refractory multiple myeloma (RRâ€MM). American Journal of Hematology, 2016, 91, 806-811.	2.0	9
481	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia and Lymphoma, 2017, 58, 1506-1508.	0.6	9
482	The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis. Hormones, 2018, 17, 153-166.	0.9	9
483	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Annals of Hematology, 2019, 98, 1427-1434.	0.8	9
484	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leukemia and Lymphoma, 2019, 60, 619-628.	0.6	9
485	Long PFS of more than 7Âyears is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. Annals of Hematology, 2020, 99, 1257-1264.	0.8	9
486	Realâ€world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Grecoâ€Israeli collaborative myeloma working group. American Journal of Hematology, 2020, 95, 465-471.	2.0	9

#	Article	IF	Citations
487	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e905-e909.	0.2	9
488	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. Cancers, 2021, 13, 1257.	1.7	9
489	How I treat elderly patients with plasma cell dyscrasias. Aging, 2018, 10, 4248-4268.	1.4	9
490	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. Cancers, 2022, 14, 2796.	1.7	9
491	Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia. Haematologia, 2002, 32, 169-173.	0.2	8
492	Danazol Therapy for Thrombocytopenia in Patients with Myelodysplastic Syndromes. Acta Haematologica, 2002, 107, 234-236.	0.7	8
493	Serum homocysteine, folate and vitamin B12 in patients with Pagetâ€™s disease of bone: the effect of zoledronic acid. Journal of Bone and Mineral Metabolism, 2010, 28, 314-319.	1.3	8
494	Short progressionâ€free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agentâ€based therapy. European Journal of Haematology, 2011, 87, 323-329.	1.1	8
495	Bisphosphonate Anticancer Activity in Multiple Myeloma. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 123-128.	0.9	8
496	Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. American Journal of Hematology, 2012, 87, 734-736.	2.0	8
497	Haemophilia and low bone mass. Ok, but what about fracture risk?. Haemophilia, 2016, 22, 11-14.	1.0	8
498	<scp>TLR</scp>4/<scp>TIRAP</scp> polymorphisms are associated with progression and survival of patients with symptomatic myeloma. British Journal of Haematology, 2016, 172, 44-47.	1.2	8
499	Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis. Blood Cancer Journal, 2017, 7, e597-e597.	2.8	8
500	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. Expert Review of Anticancer Therapy, 2019, 19, 921-928.	1.1	8
501	Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. MDM Policy and Practice, 2019, 4, 238146831881425.	0.5	8
502	Treatment of Bingâ€“Neel syndrome with first line sequential chemoimmunotherapy. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10	0.4	8
503	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. American Journal of Roentgenology, 2021, 216, 742-751.	1.0	8
504	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. Cancers, 2021, 13, 4047.	1.7	8

#	Article	IF	Citations
505	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 259-266.	1.4	8
506	Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study. Blood, 2018, 132, 1969-1969.	0.6	8
507	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1Î± and Angiogenic Cytokines.. Blood, 2006, 108, 3541-3541.	0.6	8
508	Serum Dickkopf-1 Is Increased and Correlates with Bone Mineral Density in Patients with Thalassemia-Induced Osteoporosis. Reduction Post Zoledronic Acid Administration. Blood, 2008, 112, 3889-3889.	0.6	8
509	Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).. Journal of Clinical Oncology, 2018, 36, TPS8059-TPS8059.	0.8	8
510	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. Annals of Translational Medicine, 2020, 8, 1603-1603.	0.7	8
511	Elucidating Carfilzomibâ€™s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. International Journal of Molecular Sciences, 2021, 22, 10956.	1.8	8
512	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. Biomedicines, 2021, 9, 1811.	1.4	8
513	The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells. Biomedicines, 2022, 10, 209.	1.4	8
514	Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma. Therapeutic Advances in Hematology, 2022, 13, 204062072210900.	1.1	8
515	Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies. Frontiers in Immunology, 2022, 13, .	2.2	8
516	Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e179-e181.	0.2	7
517	Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries. Journal of Bone Oncology, 2016, 5, 185-193.	1.0	7
518	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Annals of Hematology, 2017, 96, 1707-1714.	0.8	7
519	Going the distance: Are we losing patients along the multiple myeloma treatment pathway?. Critical Reviews in Oncology/Hematology, 2018, 126, 19-23.	2.0	7
520	Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. European Journal of Haematology, 2018, 100, 10-19.	1.1	7
521	Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19. Gynecologic Oncology Reports, 2020, 33, 100615.	0.3	7
522	Antibody therapies for multiple myeloma. Expert Opinion on Biological Therapy, 2020, 20, 295-303.	1.4	7

#	Article	IF	Citations
523	Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment. Haematologica, 2020, 105, 859-861.	1.7	7
524	TP53 mutations determined by targeted NGS in breast cancer: a case-control study. Oncotarget, 2021, 12, 2206-2214.	0.8	7
525	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. HemaSphere, 2021, 5, e614.	1.2	7
526	Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy. International Journal of Molecular Sciences, 2021, 22, 10406.	1.8	7
527	Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib. Blood, 2010, 116, 2963-2963.	0.6	7
528	Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease. Blood, 2012, 120, 1819-1819.	0.6	7
529	Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma. Medical Science Monitor, 2013, 19, 1188-1194.	0.5	7
530	Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. Oncotarget, 2018, 9, 36906-36913.	0.8	7
531	Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. Clinical Nephrology, 2016, 85 (2016), 44-54.	0.4	7
532	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2022, 25, 117-118.	2.0	7
533	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. Blood, 2021, 138, 76-76.	0.6	7
534	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. Blood, 2020, 136, 48-49.	0.6	7
535	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. Biomedicines, 2022, 10, 204.	1.4	7
536	Increased CD177 (PRV1) expression in thalassaemia and the underlying erythropoietic activity. British Journal of Haematology, 2008, 141, 100-104.	1.2	6
537	Pegylated Interferon plus Ribavirin Combination Therapy for Chronic Hepatitis C in Patients with Congenital Coagulation Disorders. Acta Haematologica, 2008, 120, 63-69.	0.7	6
538	First-line bortezomib benefits patients with multiple myeloma. Nature Reviews Clinical Oncology, 2009, 6, 683-685.	12.5	6
539	Circulating periostin in patients with nonalcoholic fatty liver disease. Endocrine, 2017, 56, 438-441.	1.1	6
540	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. Hematological Oncology, 2017, 35, 734-740.	0.8	6

#	Article	IF	Citations
541	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leukemia and Lymphoma, 2018, 59, 2002-2004.	0.6	6
542	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones, 2018, 17, 573-579.	0.9	6
543	Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. Hematology, 2019, 24, 318-324.	0.7	6
544	A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of Medical Economics, 2019, 22, 766-776.	1.0	6
545	The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients.. Blood, 2009, 114, 1815-1815.	0.6	6
546	High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia. Blood, 2010, 116, 1010-1010.	0.6	6
547	Liver Transient Elastography (FibroScan) Correlates with Liver Iron Concentration and Reflects Liver Fibrosis In Patients with Sickle Cell Disease. Blood, 2010, 116, 1646-1646.	0.6	6
548	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. Cancers, 2021, 13, 5057.	1.7	6
549	The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia. Blood, 2015, 126, 2284-2284.	0.6	6
550	Healthâ€related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone Â± subcutaneous daratumumab: Patientâ€reported outcomes from the APOLLO trial. American Journal of Hematology, 2022, 97, 481-490.	2.0	6
551	Systemic lupus erythematosus presenting as myelofibrosis. Haematologia, 1998, 29, 153-6.	0.2	6
552	Immune response and adverse events after vaccination against <scp>SARSâ€CoV</scp>â€2 in adult patients with transfusionâ€dependent thalassaemia. British Journal of Haematology, 2022, 197, 576-579.	1.2	6
553	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study â€œREBUILDâ€. Cancers, 2022, 14, 2768.	1.7	6
554	Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals. HemaSphere, 2022, 6, e747.	1.2	6
555	Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. Annals of Hematology, 2002, 81, 182-186.	0.8	5
556	Macrophage Inflammatory Protein-1 alpha (MIP-1alpha) is over-expressed in a cohort of patients with myelodysplastic syndromes. European Journal of Haematology, 2005, 75, 85-86.	1.1	5
557	Evaluation of bone involvement in patients with Gaucher disease: a semiâ€quantitative magnetic resonance imaging method (using ROI estimation of bone lesion) as an alternative method to semiâ€quantitative methods used so far. European Journal of Haematology, 2015, 95, 342-351.	1.1	5
558	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 431-437.	0.2	5

#	Article	IF	Citations
559	The Spectrum of Ocular Manifestations in Patients with WaldenstrÃ¶mâ€™s Macroglobulinemia. Ocular Immunology and Inflammation, 2021, , 1-10.	1.0	5
560	Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma. Viruses, 2021, 13, 1844.	1.5	5
561	Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG). Blood, 2018, 132, 1971-1971.	0.6	5
562	VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.. Blood, 2006, 108, 794-794.	0.6	5
563	Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy.. Blood, 2007, 110, 1484-1484.	0.6	5
564	Hyperphosphorylated Pararg-7 Is a Frequent Antigenic Target of IgM Paraproteins, Is Dominantly Inherited and Represents a Highly Significant Risk Factor for Monoclonal Gammopathy of Undetermined Significance of the IgM Type (IgM-MGUS) and Waldenstrom's Macroglobulinemia (WM), Allowing for the Identification of Family Members at Risk in Cases of Familial IgM-MGUS and WM.. Blood, 2009, 114, 3935-3935.	0.6	5
565	Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient. Blood, 2013, 122, 3195-3195.	0.6	5
566	Plasma Cell Leukemia â€“ Facts and Controversies: More Questions than Answers?. Clinical Hematology International, 2020, 2, 133.	0.7	5
567	Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma â‰¥80 Years of Age: An Analysis of the Greek Myeloma Study Group. Blood, 2011, 118, 5084-5084.	0.6	5
568	Kinetics of <scp>antiâ€SARSâ€CoV</scp>â€2 neutralizing antibodies development after <scp>BNT162b2</scp> vaccination in patients with amyloidosis and the impact of therapy. American Journal of Hematology, 2022, 97, E27.	2.0	5
569	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Blood, 2021, 138, 3886-3886.	0.6	5
570	Decreased incidence of EPCR 4678G/C SNP in multiple myeloma patients with thrombosis. Thrombosis Research, 2013, 132, 400-401.	0.8	4
571	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2017, 16, 1-9.	1.0	4
572	When to recommend a second autograft in patients with relapsed myeloma?. Leukemia and Lymphoma, 2017, 58, 781-787.	0.6	4
573	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or) Tj ETQq1 1 0.784314 rgBT /Ove 2018, 59, 983-987.	0.6	4
574	Nonâ€lethal proteasome inhibition activates proâ€tumorigenic pathways in multiple myeloma cells. Journal of Cellular and Molecular Medicine, 2019, 23, 8010-8018.	1.6	4
575	Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma. Blood, 2019, 134, 3118-3118.	0.6	4
576	Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients. Blood, 2019, 134, 4338-4338.	0.6	4

#	Article	IF	Citations
577	Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study. Blood, 2020, 136, 42-44.	0.6	4
578	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities.. Blood, 2009, 114, 958-958.	0.6	4
579	Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma. Blood, 2010, 116, 2967-2967.	0.6	4
580	Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma. Blood, 2010, 116, 2969-2969.	0.6	4
581	Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group. Blood, 2011, 118, 5083-5083.	0.6	4
582	Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment. Blood, 2013, 122, 3090-3090.	0.6	4
583	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. Blood, 2014, 124, 306-306.	0.6	4
584	Distinct Immunogenetic Signatures in IgA Versus IgG Multiple Myeloma. Blood, 2016, 128, 2062-2062.	0.6	4
585	The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1â€“3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.. Blood, 2007, 110, 1475-1475.	0.6	4
586	Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy. Blood, 2013, 122, 3723-3723.	0.6	4
587	IMiDs for myeloma induced renal impairment. Oncotarget, 2018, 9, 35476-35477.	0.8	4
588	Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study. Blood, 2018, 132, 3289-3289.	0.6	4
589	Consumption of Fruits, Vegetables and Bladder Cancer Risk: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. Nutrition and Cancer, 2022, 74, 2003-2016.	0.9	4
590	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 2736-2736.	0.6	4
591	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. Blood, 2020, 136, 21-21.	0.6	4
592	Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel. Blood, 2020, 136, 38-39.	0.6	4
593	Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recoveryâ€"The Prospective Observational ROADMAP-Post COVID-19 Study. Hemato, 2022, 3, 111-121.	0.2	4
594	Severe aplastic anaemia relapsing during a pregnancy; spontaneous remission following termination. Haematologia, 1998, 29, 147-51.	0.2	4

#	Article	IF	Citations
595	Interactions between osteoclasts, osteoblasts and immune cells: implications for the pathogenesis of bone loss in thalassemia. Pediatric Endocrinology Reviews, 2008, 6 Suppl 1, 94-106.	1.2	4
596	Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients. Viruses, 2022, 14, 758.	1.5	4
597	Oxidative stress and endogenous DNA damage in blood mononuclear cells may predict anti-SARS-CoV-2 antibody titers after vaccination in older adults. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166393.	1.8	4
598	Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. Journal of Clinical Medicine, 2022, 11, 3355.	1.0	4
599	Bisphosphonate treatment for the management of osteoporosis in beta-thalassaemia. British Journal of Haematology, 2004, 125, 93-94.	1.2	3
600	Dual-Energy X-Ray Absorptiometry and Quantitative Ultrasound in Patients With Paget's Disease of Bone Before and After Treatment With Zoledronic Acid: Association With Serum Bone Markers and Dickkopf-1. Journal of Clinical Densitometry, 2010, 13, 190-196.	0.5	3
601	Advances in the treatment of multiple myeloma. European Journal of Cancer, 2011, 47, S306-S308.	1.3	3
602	Increased RANKL and IL-6 levels might result in high bone turnover in a case of a CD34+/CD117+/myeloperoxidase+dim acute myeloid leukemia presenting with severe hypercalcemia and lumbar spine fractures. Leukemia Research, 2011, 35, e188-e189.	0.4	3
603	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. Leukemia and Lymphoma, 2016, 57, 1776-1780.	0.6	3
604	Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. Journal of Bone and Mineral Metabolism, 2018, 36, 399-409.	1.3	3
605	Reply to Commentâ€"Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology. Dentistry Journal, 2019, 7, 54.	0.9	3
606	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. Leukemia and Lymphoma, 2020, 61, 3247-3250.	0.6	3
607	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. Cancers, 2021, 13, 763.	1.7	3
608	Integrin expression in correlation to clinicopathological features and prognosis of prostate cancer: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 221-232.	0.8	3
609	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. Blood, 2018, 132, 1966-1966.	0.6	3
610	Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.. Blood, 2008, 112, 1725-1725.	0.6	3
611	A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.. Blood, 2009, 114, 428-428.	0.6	3
612	The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD) Tj ETQq0 0 0 rgBT /Overlock 10 T Prospective Multicenter Study. Blood, 2010, 116, 3052-3052.	0.6	3

#	Article	IF	Citations
613	Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study. Blood, 2010, 116, 5071-5071.	0.6	3
614	Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury.. Blood, 2012, 120, 2919-2919.	0.6	3
615	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. Blood, 2014, 124, 2113-2113.	0.6	3
616	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. Blood, 2014, 124, 4738-4738.	0.6	3
617	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. Blood, 2015, 126, 4201-4201.	0.6	3
618	The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).. Blood, 2007, 110, 1490-1490.	0.6	3
619	Continuous Improvement of Bone Mineral Density Two Years Post Zoledronic Acid Discontinuation in Patients with Thalassemia-Induced Osteoporosis: Long-Term Follow-Up of a Randomized, Placebo-Controlled Trial.. Blood, 2007, 110, 2768-2768.	0.6	3
620	Primary Therapy of Waldenstroì‘m's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. Blood, 2010, 116, 1941-1941.	0.6	3
621	Novel agents for the management of myelodysplastic syndromes. Medical Science Monitor, 2006, 12, RA194-206.	0.5	3
622	Carfilzomib 56â€‰mg/m² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison. Leukemia and Lymphoma, 2022, 63, 1887-1896.	0.6	3
623	Fetal Erythropoiesis after Allogeneic Bone Marrow Transplantation Estimated by the Peripheral Blood Erythrocytes Containing Hemoglobin F (F-cells). Hematology, 2001, 5, 447-453.	0.7	2
624	Antibodies to dickkopf-1 protein. Expert Opinion on Therapeutic Patents, 2006, 16, 1453-1458.	2.4	2
625	Antibodies to receptor activator of nuclear factor-Î² B ligand (RANKL). Expert Opinion on Therapeutic Patents, 2008, 18, 1265-1269.	2.4	2
626	Reply to C.A. Hutchison et al. Journal of Clinical Oncology, 2011, 29, e314-e314.	0.8	2
627	Less strength and more fractures for MGUS bones. Blood, 2014, 123, 603-604.	0.6	2
628	Carfilzomib for treating myeloma. Expert Opinion on Orphan Drugs, 2016, 4, 989-999.	0.5	2
629	Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. Metabolism: Clinical and Experimental, 2017, 71, 198-201.	1.5	2
630	Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. Bone Marrow Transplantation, 2017, 52, 1537-1542.	1.3	2

#	Article	IF	Citations
631	Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study. Journal of Bone Oncology, 2018, 10, 49-56.	1.0	2
632	Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a caseâ€“control study . OncoTargets and Therapy, 2019, Volume 12, 4195-4202.	1.0	2
633	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 23-28.	0.2	2
634	Screening for Gaucher disease among patients with plasma cell dyscrasias. Leukemia and Lymphoma, 2021, 62, 761-763.	0.6	2
635	Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World â€œPOWERFULâ€•Study. Journal of Clinical Medicine, 2021, 10, 1509.	1.0	2
636	ASSOCIATION OF -308G/A, -238G/A TNF-Î± POLYMORPHISMS WITH MULTIPLE MYELOMA RISK AND SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS.. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	2
637	Periostin and sclerostin levels in juvenile Pagetï¿½s disease. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 269.	1.0	2
638	Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study). Blood, 2019, 134, 1837-1837.	0.6	2
639	Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study. Blood, 2019, 134, 1845-1845.	0.6	2
640	Zoledronic Acid Is an Effective Treatment for Osteoporosis in Patients with Thalassemia Major: Results of a Randomized, Placebo-Controlled, Trial.. Blood, 2005, 106, 3656-3656.	0.6	2
641	Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.. Blood, 2007, 110, 2739-2739.	0.6	2
642	The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.. Blood, 2007, 110, 3596-3596.	0.6	2
643	Zoledronic Acid Increases Bone Mineral Density in Patients with Thalassemia Intermedia-Induced Osteoporosis Regardless of the Incessant Bone Marrow Expansion.. Blood, 2007, 110, 3813-3813.	0.6	2
644	Prolonged Administration of Hydroxyurea Reduces Morbidity and Mortality in Adult Patients with Sickle-Cell Syndromes: Long-Term Experience of a Single Center.. Blood, 2008, 112, 1445-1445.	0.6	2
645	Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis.. Blood, 2009, 114, 3863-3863.	0.6	2
646	Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma. Blood, 2012, 120, 4028-4028.	0.6	2
647	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 1860-1860.	0.6	2
648	The Novel Proteasome Inhibitors Carfilzomib and Oprozomib Induce Milder Degenerative Effects Compared To Bortezomib When Administered Via Oral Feeding In An In Vivo Drosophila Experimental Model: A Biological Platform To Evaluate Safety/Efficacy Of Proteasome Inhibitors. Blood, 2013, 122, 1930-1930.	0.6	2

#	Article	IF	Citations
649	Increased Von Willebrand Factor and High Circulating Placental Growth Factor Correlate with Inflammation and Iron Overload in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia. Blood, 2014, 124, 1392-1392.	0.6	2
650	The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMCs of Myeloma Patients Treated with Melphalan. Blood, 2015, 126, 3628-3628.	0.6	2
651	Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma. Blood, 2016, 128, 4491-4491.	0.6	2
652	Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.. Journal of Clinical Oncology, 2013, 31, 8589-8589.	0.8	2
653	Real-world use of carfilzomib among multiple myeloma patients with at least one prior therapy.. Journal of Clinical Oncology, 2019, 37, e19515-e19515.	0.8	2
654	Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma. Annals of Translational Medicine, 2016, 4, 510-510.	0.7	2
655	Angiogenic Molecules and Inflammatory Cytokines in Patients with Thalassemia Major and Double Heterozygous HbS/Beta-Thalassemia; the impact of Deferasirox.. Blood, 2009, 114, 2018-2018.	0.6	2
656	Competing Risk Survival Analysis In Patients With Symptomatic WaldenstrÃ¶mâ€™s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years. Blood, 2013, 122, 3197-3197.	0.6	2
657	Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study). Blood, 2019, 134, 3167-3167.	0.6	2
658	The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice. Blood, 2021, 138, 2701-2701.	0.6	2
659	Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality. Blood, 2021, 138, 1636-1636.	0.6	2
660	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Therapeutic Advances in Hematology, 2022, 13, 204062072210884.	1.1	2
661	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. Journal of Clinical Medicine, 2022, 11, 3088.	1.0	2
662	Myelodysplastic features in patients with longâ€term HIV infection and haemophilia. Haemophilia, 2001, 7, 47-52.	1.0	1
663	Have myeloma cells osteoclast-like activity?. Leukemia Research, 2008, 32, 521-522.	0.4	1
664	Reply to â€˜Proteasome inhibition therapies in childhood cancerâ€™ by Zaman et al.. Leukemia, 2008, 22, 884-885.	3.3	1
665	Bortezomib down-regulates the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease. Leukemia Research, 2010, 34, 700-701.	0.4	1
666	Zoledronic acid: A framework of emerging anticancer evidence throughout the cancer continuum. Critical Reviews in Oncology/Hematology, 2011, 77, S1-S2.	2.0	1

#	Article	IF	Citations
667	Denosumab Compared with Zoledronic Acid for Preventing Skeletal Complications in Patients with Multiple Myeloma: A Randomized, Phase 3, Double-Blind, Double-Dummy Trial. Annals of Oncology, 2012, 23, ix360.	0.6	1
668	Serum sclerostin levels following treatment with parathyroid hormone. Journal of Endocrinological Investigation, 2013, 36, 280-280.	1.8	1
669	Biology and management of myeloma-related bone disease. Acta Haematologica Polonica, 2014, 45, 107-121.	0.1	1
670	Involvement of osteocytes in cancer bone niche. , 2015, , 65-72.		1
671	Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e127-e128.	0.2	1
672	Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. JAMA Oncology, 2016, 2, 1261.	3.4	1
673	Cadherinâ€11 (<scp>CDH</scp>11) expression in the peripheral blood of patients with active Multiple Myeloma. British Journal of Haematology, 2017, 177, 813-816.	1.2	1
674	Other Complications of Multiple Myeloma. Hematologic Malignancies, 2018, , 141-156.	0.2	1
675	Study of bone metabolism and angiogenesis in patients undergoing highâ€dose chemotherapy/autologous hematopoietic stem cell transplantation. European Journal of Haematology, 2018, 100, 131-139.	1.1	1
676	A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S247-S248.	0.2	1
677	Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Review of Hematology, 2018, 11, 463-469.	1.0	1
678	Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. Endocrine, 2018, 62, 487-489.	1.1	1
679	GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. Clinical and Experimental Nephrology, 2019, 23, 199-206.	0.7	1
680	Real World Treatment of Patients with Relapsed/Refractory Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S24-S27.	0.2	1
681	Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density. Annals of Hematology, 2019, 98, 1583-1592.	0.8	1
682	PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US. HemaSphere, 2019, 3, 652-653.	1.2	1
683	Primary Treatment of Light Chain (AL) Amyloidosis With Bortezomib, Lenalidomide and Dexamethasone (VRD) or with Bortezomib, Cyclophosphamide and Dexamethasone (VCD/CyBorD): efficacy and toxicity. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e320-e321.	0.2	1
684	Real-World Evidence of the Use of Carfilzomib and Dexamethasone According to Age Subgroup: An Interim Analysis From a Prospective Observational Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e282-e283.	0.2	1

#	Article	IF	Citations
685	Real-World Use of Carfilzomib Therapy Among Patients With Existing Cardiovascular Medical History: An Analysis of a Prospective Observational Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e281-e282.	0.2	1
686	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. Journal of Clinical Medicine, 2020, 9, 3201.	1.0	1
687	Response of an oncology unit in the midst of the COVID-19 outbreak. Journal of Oncology Pharmacy Practice, 2020, 26, 1947-1952.	0.5	1
688	Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group. Blood, 2018, 132, 3295-3295.	0.6	1
689	Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients. Blood, 2019, 134, 4326-4326.	0.6	1
690	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS). Blood, 2019, 134, 3126-3126.	0.6	1
691	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. Blood, 2019, 134, 5528-5528.	0.6	1
692	Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study. Blood, 2020, 136, 1-2.	0.6	1
693	Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.. Blood, 2006, 108, 506-506.	0.6	1
694	Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.. Blood, 2007, 110, 191-191.	0.6	1
695	Increased Bone Resorption Is Implicated in the Pathogenesis of Bone Loss in Hemophilia Patients: Correlations with Severity of Hemophilic Arthropathy and HIV Infection.. Blood, 2007, 110, 493-493.	0.6	1
696	Deferasirox Reduces Serum TNF-Î± but Impairs Renal Function in Patients with Thalassemia Major after 12 Months of Therapy. Blood, 2008, 112, 3888-3888.	0.6	1
697	First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).. Blood, 2009, 114, 1951-1951.	0.6	1
698	Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents.. Blood, 2009, 114, 955-955.	0.6	1
699	Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens. Blood, 2010, 116, 3033-3033.	0.6	1
700	Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. Blood, 2011, 118, 806-806.	0.6	1
701	High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern; Implications Into the Biology of Myeloma Bone Disease. Blood, 2012, 120, 3967-3967.	0.6	1
702	Increased Serum Transforming Growth Factor-beta1 (Tgf-beta1) Is Related to a Better Outcome in MM, WM and CLL Patients. Blood, 2012, 120, 4976-4976.	0.6	1

#	Article	IF	Citations
703	Vascular Cell Adhesion Molecule-1 Is An Independent Prognostic Factor For Newly-Diagnosed Patients With Multiple Myeloma; Reductions Post VD and Rd In Myeloma Patients At First Relapse. Blood, 2013, 122, 1916-1916.	0.6	1
704	Molecular Analyses Of The Effects Induced By Orally Administered Bortezomib In Drosophila Flies: A Novel In Vivo Experimental Platform To Screen For The Tissue- and Age-Dependent Effects Of Proteasome Inhibitors. Blood, 2013, 122, 2910-2910.	0.6	1
705	Toll-Like Receptor Activation Promotes Multiple Myeloma Cell Growth and Survival By Suppression Of Endoplasmic Reticulum Stress Factor CHOP. Blood, 2013, 122, 3112-3112.	0.6	1
706	The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA). Blood, 2013, 122, 3196-3196.	0.6	1
707	Circulating Periostin Is Elevated In Patients With Hemoglobinopathies and Correlates With Bone Mineral Density In Double Heterozygous Sickle-Cell/Beta-Thalassemia Patients; A Novel Marker Of Bone Strength?. Blood, 2013, 122, 3445-3445.	0.6	1
708	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. Blood, 2014, 124, 4769-4769.	0.6	1
709	Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important. Blood, 2016, 128, 3310-3310.	0.6	1
710	Evaluation of Experimental Retreatment and Prolonged Therapy with Subcutaneous (SC) Bortezomib in Patients (Pts) with Multiple Myeloma in First or Second Relapse, a Randomized, Controlled, Phase 3 Study. Blood, 2016, 128, 3328-3328.	0.6	1
711	Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. Blood, 2016, 128, 648-648.	0.6	1
712	Anti-Angiogenic Effect of Bortezomib in Multiple Myeloma Patients.. Blood, 2004, 104, 4912-4912.	0.6	1
713	Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens.. Blood, 2007, 110, 4745-4745.	0.6	1
714	Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma.. Blood, 2007, 110, 1499-1499.	0.6	1
715	Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.. Blood, 2007, 110, 1482-1482.	0.6	1
716	Treatment with Deferasirox Effectively Decreases Iron Burden in Patients with Sickle Cell Disease and Thalassemia Intermedia.. Blood, 2009, 114, 1517-1517.	0.6	1
717	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Long Term Follow-up Analysis of a Phase II Study.. Blood, 2009, 114, 2887-2887.	0.6	1
718	The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients,. Blood, 2011, 118, 3961-3961.	0.6	1
719	High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenstroì̂m Macroglobulinemia. Blood, 2011, 118, 2893-2893.	0.6	1
720	Circulating Activin-A Is Elevated in Patients with Thalassemia Major and Double Heterozygous Sickle-Cell/Beta-Thalassemia and Correlates with Markers of Hemolysis and Bone Mineral Density. Blood, 2012, 120, 3256-3256.	0.6	1

#	Article	IF	Citations
721	Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients â‰¤65 Years of Age Compared to Patients >65 Years. Blood, 2012, 120, 4030-4030.	0.6	1
722	The Role of Angiopoietins System in Waldenstrom's Macroglobulinemia: Correlations with Marrow Microvessel Density and Survival. Blood, 2012, 120, 3901-3901.	0.6	1
723	Outcomes of Primary Systemic Light Chain (AL) Amyloidosis in Patients Treated Upfront with Novel Agents and the Importance of Risk Adapted Treatment Strategies. Blood, 2012, 120, 1786-1786.	0.6	1
724	High C-Terminal Cross-Linking Telopeptide of Collagen Type-I (CTX) Predicts for Poor Overall Survival in Patients with Multiple Myeloma Who Receive Frontline Therapy with Immunomodulatory Drugs (IMiDs) but Not with Bortezomib-Based Regimens. Blood, 2012, 120, 935-935.	0.6	1
725	Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction. Blood, 2013, 122, 3176-3176.	0.6	1
726	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. Blood, 2013, 122, 1867-1867.	0.6	1
727	Lenalidomide Administration In Patients With POEMS Syndrome. Blood, 2013, 122, 3235-3235.	0.6	1
728	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. Blood, 2014, 124, 3461-3461.	0.6	1
729	Iron Overload of the Kidneys of Patients with Thalassemia and Sickle-Cell Disease: Final Results of a Prospective Study in 224 Patients Using Magnetic Resonance Imaging T2 and R2* Techniques. Blood, 2015, 126, 2157-2157.	0.6	1
730	Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice. Blood, 2015, 126, 3034-3034.	0.6	1
731	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Blood, 2015, 126, 4188-4188.	0.6	1
732	Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group. Blood, 2018, 132, 1978-1978.	0.6	1
733	Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. Blood, 2018, 132, 1968-1968.	0.6	1
734	Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece. Blood, 2019, 134, 5340-5340.	0.6	1
735	Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis. Blood, 2019, 134, 1894-1894.	0.6	1
736	Aortic hemodynamic parameters as predictors of incident or deteriorating hypertension during carfilzomib therapy in patients with relapsed multiple myeloma. European Heart Journal, 2021, 42, .	1.0	1
737	Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes. Blood, 2021, 138, 1668-1668.	0.6	1
738	Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study. Blood, 2021, 138, 2737-2737.	0.6	1

#	Article	IF	Citations
739	The Compass-COVID19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. Blood, 2021, 138, 2121-2121.	0.6	1
740	Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study. Blood, 2021, 138, 2729-2729.	0.6	1
741	Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison. Blood, 2020, 136, 8-9.	0.6	1
742	Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase Î±. Blood, 2020, 136, 34-35.	0.6	1
743	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. Blood, 2020, 136, 25-25.	0.6	1
744	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. Blood, 2020, 136, 33-33.	0.6	1
745	T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. Blood, 2020, 136, 28-28.	0.6	1
746	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. Hemato, 2022, 3, 188-203.	0.2	1
747	Thrombophilic Factors in Patients with Syndrome X. Thrombosis Research, 2000, 97, 525-527.	0.8	0
748	Reply - Is ibandronate effective in multiple myeloma?. European Journal of Haematology, 2003, 71, 471-472.	1.1	0
749	Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease. Clinical Lymphoma and Myeloma, 2009, 9, S30-S32.	1.4	0
750	Intravenous pamidronate for myeloma bone disease: can the dose be lowered?. Lancet Oncology, The, 2010, 11, 913-914.	5.1	0
751	Zoledronic acid for all patients with newly diagnosed multiple myeloma?. Lancet Oncology, The, 2011, 12, 711-712.	5.1	0
752	New Insights in WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2012, , 223-236.		0
753	Imatinib and chronic myeloid leukemia: close to the bone. Leukemia and Lymphoma, 2013, 54, 1581-1582.	0.6	0
754	Comparison of Denosumab Vs Zoledronic Acid for Treatment of Bone Disease in Adults with Newly Diagnosed Multiple Myeloma: a Randomized, Double-Blind, Multinational Phase 3 Trial. Annals of Oncology, 2014, 25, iv540.	0.6	0
755	AB0047â€…Cd55 Red-Cell Expression in Systemic Autoimmune Disease Reflects Its Impact on Erythropoiesis through Immune-Mediated Bone Marrow Insufficiency. Annals of the Rheumatic Diseases, 2014, 73, 819.3-819.	0.5	0
756	Outcome of first salvage therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, observational, non-interventional EMMOS study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e274-e275.	0.2	0

#	Article	IF	Citations
757	Outcome of treatment for first versus later relapse in multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e277-e278.	0.2	0
758	High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e223-e224.	0.2	0
759	Improved tumor response and survival outcomes with post-transplant bortezomib (Btz) consolidation versus observation (Obs) alone in patients with newly diagnosed multiple myeloma (MM): Results from a randomized, open-label, multicenter, parallel-group phase 2 study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e129-e130.	0.2	0
760	Deficiency in DNA repair pathways of peripheral blood mononuclear cells correlates with better clinical outcome of myeloma patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e242-e243.	0.2	0
761	Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S76-S77.	0.2	0
762	Budget Impact Analysis of Panobinostat â€“ Bortezomib and Dexamethasone, As 3rd Or 4th Line of Treatment in Patients with Relapsed/Refractory Multiple Myeloma in Greece. Value in Health, 2016, 19, A729.	0.1	0
763	Management of Early Relapse, How to Navigate the Choices. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S137-S139.	0.2	0
764	Increased Semaphorin-4D and Plexin-B1 Levels in Multiple Myeloma Patients May Contribute to Osteolytic Bone Disease. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S332.	0.2	0
765	RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e143.	0.2	0
766	Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e40.	0.2	0
767	Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e62-e63.	0.2	0
768	Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e115-e116.	0.2	0
769	Bone Disease. Hematologic Malignancies, 2018, , 111-140.	0.2	0
770	The role of ibrutinib in WaldenstrÃ¶m macroglobulinemia. Expert Opinion on Orphan Drugs, 2018, 6, 85-89.	0.5	0
771	Multiple Myeloma: Criteria for Diagnosis and Response to Therapy. , 2018, , 651-658.		0
772	Multiple Myeloma: How to Use Modern Imaging in Every Day Clinical Practice?. , 2018, , 671-676.		0
773	Emerging Data on Management and Imaging of Myeloma Bone Disease. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S80-S82.	0.2	0
774	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy NaÃ¯ve Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. The Observational ROADMAT-CAT-MM Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S235-S236.	0.2	0

#	Article	IF	Citations
775	Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S250-S251.	0.2	0
776	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S331-S332.	0.2	0
777	Multiple Myeloma Bone Disease. , 2019, , 329-340.		0
778	A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e4-e5.	0.2	0
779	Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e185-e186.	0.2	0
780	Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e121-e122.	0.2	0
781	Al amyloidosis with cardiac involvement: cardiotoxicity of aggregation prone peptides deriving from variable domains of immunoglobulin light chains. European Heart Journal, 2020, 41, .	1.0	0
782	MM-167: Phenotypic and Prognostic Evaluation of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Detected with Next-Generation Flow Cytometry (NGF). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S297-S298.	0.2	0
783	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. Leukemia and Lymphoma, 2020, 61, 2246-2249.	0.6	0
784	Therapy of Myeloma Bone Disease. , 2021, , 111-137.		0
785	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. , 2021, 41, .		0
786	Antibody Therapies for Multiple Myeloma. , 0, , .		0
787	Osteocytes and bone tumor niche. , 2022, , 171-178.		0
788	Recent therapeutic approaches in myeloma. , 2022, , 1019-1029.		0
789	Peripheral vascular involvement in transthyretin cardiac amyloidosis. A comparative analysis with AL amyloidosis. European Heart Journal, 2021, 42, .	1.0	0
790	The Serum Levels of N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP) Is a Strong Indicator of Pulmonary Hypertension in Patients with Sickle Cell/Beta Thalassemia.. Blood, 2006, 108, 1207-1207.	0.6	0
791	Melphalan-Induced DNA Damage In Vitro as Predictor for Clinical Outcome in Multiple Myeloma.. Blood, 2006, 108, 60-60.	0.6	0
792	The International Prognostic Scoring System for Waldestromâ€™s Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.. Blood, 2007, 110, 3615-3615.	0.6	0

#	Article	IF	Citations
793	Recombinant Human Erythropoietin May Negatively Influence Survival in Newly Diagnosed Patients with Multiple Myeloma: A Single Center Experience in 246 Patients.. Blood, 2007, 110, 4814-4814.	0.6	0
794	High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features.. Blood, 2007, 110, 4781-4781.	0.6	0
795	The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.. Blood, 2007, 110, 1478-1478.	0.6	0
796	Symptomatic Waldenstromâ€™s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.. Blood, 2007, 110, 4730-4730.	0.6	0
797	High Bone Turnover and Increased Angiogenesis Cytokines in Patients with POEMS Syndrome.. Blood, 2007, 110, 3525-3525.	0.6	0
798	Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients. Blood, 2008, 112, 5143-5143.	0.6	0
799	Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis. Blood, 2008, 112, 2731-2731.	0.6	0
800	Regulation of Multiple Myeloma Survival and Progression by CD1d. Blood, 2008, 112, 2720-2720.	0.6	0
801	Strong Correlation Between Angiogenesis and Macrophage Counts in Waldenstromâ€™s Macroglobulinemia: Implications into the Biology of the Disease. Blood, 2008, 112, 5108-5108.	0.6	0
802	Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG). Blood, 2008, 112, 655-655.	0.6	0
803	Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trephine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2008, 112, 5119-5119.	0.6	0
804	The Administration of Bortezomib, Dexamethasone and Thalidomide (VTD) after ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Normalizes sRANKL, Dickkopf-1 and Improves Abnormal Osteoclast Function and Impaired Angiogenesis.. Blood, 2008, 112, 1728-1728.	0.6	0
805	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met.. Blood, 2008, 112, 1726-1726.	0.6	0
806	Increased Plasma Levels of NGAL and IL-18 Correlate with Reduced GFR Providing Two Novel Biomarkers for Kidney Injury Assessment: Evidence of Early Tubuloglomerular Defect in Patients with HbS/b-Thalassemia. Blood, 2008, 112, 4805-4805.	0.6	0
807	Correlation of Erythropoietin Stimulating Agents (ESAs) with the Post-Therapy Micro-Vessel Density (MVD) in Newly Diagnosed Myeloma Patients: a Possible Mechanism of ESAs Association with Reduced Survival Rates.. Blood, 2009, 114, 4873-4873.	0.6	0
808	Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens.. Blood, 2009, 114, 1824-1824.	0.6	0
809	Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation.. Blood, 2009, 114, 3334-3334.	0.6	0
810	High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma.. Blood, 2009, 114, 1819-1819.	0.6	0

#	Article	IF	Citations
811	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH).. Blood, 2009, 114, 2845-2845.	0.6	0
812	The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients.. Blood, 2009, 114, 2279-2279.	0.6	0
813	Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.. Blood, 2009, 114, 3871-3871.	0.6	0
814	Alterations in the Epigenetic Network Controlling Transcription Activity, Chromatin Structure and Region-Specific Repair of Different Genomic Loci Predicts Clinical Outcome in Multiple Myeloma.. Blood, 2009, 114, 122-122.	0.6	0
815	A Polymerase Chain Reaction-Based Method to Detect Gene-Specific Adducts Induced by Anticancer Drugs. Clinical Application in Multiple Myeloma.. Blood, 2009, 114, 1879-1879.	0.6	0
816	Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.. Blood, 2009, 114, 829-829.	0.6	0
817	Primary Therapy of Waldnestrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network.. Blood, 2009, 114, 2886-2886.	0.6	0
818	Biochemical Markers of Bone Remodeling in Multiple Myeloma. , 2010, , 63-89.		0
819	Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis. Blood, 2010, 116, 3048-3048.	0.6	0
820	Over-Expression of RANKL In Invariant NKT Cells Is Characteristic of Active Myeloma but Not of MGUS or Asymptomatic Myeloma. Blood, 2010, 116, 4049-4049.	0.6	0
821	Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma Who Are Older Than 65 Years. Blood, 2010, 116, 1947-1947.	0.6	0
822	Increased Expression of Cyclin-D1 on Trephine Bone Marrow Biopsies Independently Predicts for Shorter Overall Survival In Patients with Multiple Myeloma Treated with Novel Agents. Blood, 2010, 116, 2965-2965.	0.6	0
823	Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma. Blood, 2010, 116, 2976-2976.	0.6	0
824	Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy. Blood, 2010, 116, 3035-3035.	0.6	0
825	Differences In DNA Damage Response Pathways In the PBMCs of Patients with MGUS, Asymptomatic Myeloma and Symptomatic Multiple Myeloma. Blood, 2010, 116, 2974-2974.	0.6	0
826	The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function. Blood, 2010, 116, 3036-3036.	0.6	0
827	Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group. Blood, 2011, 118, 5085-5085.	0.6	0
828	Comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD) Study Equations and A Formula Based on Cystatin-C and Serum Creatinine for the Estimation of Glomerular Filtration Rate in Patients with Multiple Myeloma; Is It Time to Change From MDRD to CKD-EPI Equation?. Blood, 2011, 118, 5091-5091.	0.6	0

#	Article	IF	Citations
829	Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenstroì̂m's Macroglobulinemia, on Patients' Survival. Blood, 2011, 118, 2894-2894.	0.6	0
830	Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,. Blood, 2011, 118, 3926-3926.	0.6	0
831	Circulating Angiogenic Cytokines Are Elevated in Patients with Smoldering Myeloma; Implications Into Disease Biology. Blood, 2011, 118, 5059-5059.	0.6	0
832	Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma,. Blood, 2011, 118, 3920-3920.	0.6	0
833	Low Circulating Mannan-Binding Leptin Levels Correlate with Increased Number of Febrile Episodes in Myeloma Patients Who Undergo High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplantation and Do Not Receive Antibiotic Prophylaxis. Blood, 2011, 118, 4457-4457.	0.6	0
834	Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3,. Blood, 2011, 118, 3215-3215.	0.6	0
835	Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations. Blood, 2011, 118, 2872-2872.	0.6	0
836	Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome. Blood, 2011, 118, 1802-1802.	0.6	0
837	Bone Marrow Biopsy May Be Required During the Initial Evaluation of Individuals with Asymptomatic Monoclonal Gammopathy. Blood, 2011, 118, 5067-5067.	0.6	0
838	Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma. Blood, 2011, 118, 5081-5081.	0.6	0
839	High Circulating Vascular Endothelial Growth Factor Receptor-1 Correlates with Increased Microvessel Density and Inferior Survival in Newly-Diagnosed Patients with Multiple Myeloma Who Receive Frontline Therapy with Novel Agent-Based Regimens. Blood, 2011, 118, 5082-5082.	0.6	0
840	Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients. Blood, 2011, 118, 1811-1811.	0.6	0
841	Mobilization of Autologous Peripheral Blood Stem Cells with Spectra Optia v5.0: A Single Center Experience with An Automatic Interface-Controlled Apheresis System. Blood, 2011, 118, 4396-4396.	0.6	0
842	Discovering the Epigenetic Modifications and the Alterations in Cellular DNA Damage Response Pathways That Drive Myelomagenesis; Clinical Implications Into the Biology of Multiple Myeloma. Blood, 2011, 118, 299-299.	0.6	0
843	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma,. Blood, 2011, 118, 3918-3918.	0.6	0
844	Health Resource Utilisation (HRU) in Europe Associated with Skeletal-Related Events (SRES): Results from a Retrospective Study. Annals of Oncology, 2012, 23, ix447-ix448.	0.6	0
845	Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. Blood, 2012, 120, 948-948.	0.6	0
846	The Effect of Novel Anti-myeloma Agents on Bone Metabolism. , 2013, , 257-275.		0

#	Article	IF	Citations
847	The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation. Blood, 2012, 120, 1849-1849.	0.6	0
848	Lower Levels of Survivin in Patients with Leukemic Low Grade B-Cell Lymphomas Expressing LMP1 Oncoprotein of Epstein-Barr Virus. Blood, 2012, 120, 1560-1560.	0.6	0
849	A Study of the Expression of the LMP1 Oncoprotein in Low-Grade B Cell Lymphomas and Correlation with the Levels of Oxidative Stress. Blood, 2012, 120, 4833-4833.	0.6	0
850	Replacement Therapy with Imiglucerase Improves Magnetic Resonance Imaging (MRI) Abnormalities in Almost Half Patients with Non-Neuronopathic Form of Gaucher Disease After Twelve Months of Therapy: Results of a Semi-Quantitative MRI Method.. Blood, 2012, 120, 2132-2132.	0.6	0
851	The CKD-EPI-Cystatin C Equation For The Estimation Of Glomerular Filtration Rate Detects Higher Number Of Patients With Thalassemia Major and Renal Impairment, Before and After Treatment With Deferasirox; Is It Time To Change From MDRD To CKD-EPI-Cystatin C equation In Thalassemia?. Blood, 2013, 122, 3451-3451.	0.6	0
852	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. Blood, 2013, 122, 1866-1866.	0.6	0
853	Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. Blood, 2013, 122, 1861-1861.	0.6	0
854	Tubular Damage Is Present In Patients With MGUS and Asymptomatic Multiple Myeloma Even In The Absence Of Impaired Estimated Glomerular Filtration Rate; Alterations Of Neutrophil Gelatinase-Associated Lipocalin and Cystatin-C In Myeloma Patients Post IMiD- and Bortezomib-Based Regimens. Blood, 2013, 122, 3091-3091.	0.6	0
855	Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients. Blood, 2013, 122, 3130-3130.	0.6	0
856	Multiple Myeloma Patients â‰¥40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents. Blood, 2013, 122, 3226-3226.	0.6	0
857	Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers. Blood, 2013, 122, 3194-3194.	0.6	0
858	Presence Of CD55- and/Or CD59-Deficient Erythrocytes In Patients With Rheumatic Diseases: An Immune-Mediated Phenomenon?. Blood, 2013, 122, 3429-3429.	0.6	0
859	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide. Blood, 2014, 124, 5702-5702.	0.6	0
860	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. Blood, 2014, 124, 2028-2028.	0.6	0
861	Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients. Blood, 2014, 124, 3481-3481.	0.6	0
862	No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience. Blood, 2014, 124, 4752-4752.	0.6	0
863	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 2029-2029.	0.6	0
864	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2014, 124, 3462-3462.	0.6	0

#	Article	IF	Citations
865	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. Blood, 2014, 124, 3464-3464.	0.6	0
866	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. Blood, 2014, 124, 2130-2130.	0.6	0
867	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. Blood, 2014, 124, 2115-2115.	0.6	0
868	Translating Findings of Proteasome Inhibitors Effects from the in VivoDrosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. Blood, 2014, 124, 4814-4814.	0.6	0
869	Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. Blood, 2014, 124, 5741-5741.	0.6	0
870	Bone disease. , 2015, , 79-90.		0
871	Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial.. Journal of Clinical Oncology, 2015, 33, TPS8611-TPS8611.	0.8	0
872	The Simultaneous Accumulation of the Extremely Cytotoxic Interstrand Cross-Links and Double-Strand Breaks Contributes to the Successful Anti-Myeloma Therapy; The Effect of DNA Repair Inhibitors. Blood, 2015, 126, 4177-4177.	0.6	0
873	Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis. Blood, 2015, 126, 1832-1832.	0.6	0
874	Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans. Blood, 2015, 126, 3250-3250.	0.6	0
875	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide. Blood, 2015, 126, 4245-4245.	0.6	0
876	Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma. Blood, 2015, 126, 3045-3045.	0.6	0
877	Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications. Blood, 2015, 126, 3054-3054.	0.6	0
878	Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. Blood, 2015, 126, 4251-4251.	0.6	0
879	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. Blood, 2015, 126, 1074-1074.	0.6	0
880	Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma. Blood, 2015, 126, 4242-4242.	0.6	0
881	Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens. Blood, 2016, 128, 4446-4446.	0.6	0
882	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. Blood, 2016, 128, 4488-4488.	0.6	0

#	Article	IF	Citations
883	Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death. Blood, 2016, 128, 2954-2954.	0.6	0
884	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	0.6	0
885	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. Blood, 2016, 128, 3259-3259.	0.6	0
886	Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study. Blood, 2016, 128, 5681-5681.	0.6	0
887	Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents. Blood, 2016, 128, 4490-4490.	0.6	0
888	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. Blood, 2016, 128, 4500-4500.	0.6	0
889	The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25/Ferritin Molar Ratio and with Markers of Hemolysis, Endothelial Dysfunction and Angiogenesis. Blood, 2016, 128, 3646-3646.	0.6	0
890	Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival. Blood, 2016, 128, 4492-4492.	0.6	0
891	Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of Melphalan. Blood, 2016, 128, 4437-4437.	0.6	0
892	Practical Considerations for Bone Health in Multiple Myeloma. , 2018, , 131-167.		0
893	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. Blood, 2018, 132, 3247-3247.	0.6	0
894	In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study. Blood, 2018, 132, 2014-2014.	0.6	0
895	Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo. Blood, 2018, 132, 3214-3214.	0.6	0
896	Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd. Blood, 2018, 132, 3246-3246.	0.6	0
897	Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry. Blood, 2018, 132, 5463-5463.	0.6	0
898	PS1394 FLOW-MEDIATED DILATATION AND AORTIC BLOOD PRESSURE PREDICT CARDIOVASCULAR ADVERSE EVENTS DURING CARFILZOMIB TREATMENT: A PROSPECTIVE STUDY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA. HemaSphere, 2019, 3, 639-640.	1.2	0
899	Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study). Blood, 2019, 134, 1881-1881.	0.6	0
900	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. Blood, 2019, 134, 1877-1877.	0.6	0

#	Article	IF	Citations
901	Accumulation of Endogenous DNA Damage Sustain Malignant Progression and Increase Therapy Resistance in Multiple Myeloma. Blood, 2019, 134, 1788-1788.	0.6	0
902	Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma. Blood, 2019, 134, 2528-2528.	0.6	0
903	Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study. Blood, 2019, 134, 5578-5578.	0.6	0
904	Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis. Blood, 2019, 134, 1842-1842.	0.6	0
905	Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy. Blood, 2019, 134, 3797-3797.	0.6	0
906	Non Invasive Evaluation of Bone Marrow Activity in Patients with Sickle Cell Disease: Correlation with Disease Features, Genotype, Markers of Erythropoiesis, Iron Metabolism and Hydroxyurea Treatment. Blood, 2019, 134, 4821-4821.	0.6	0
907	Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study. Blood, 2019, 134, 4124-4124.	0.6	0
908	The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma. Blood, 2019, 134, 5529-5529.	0.6	0
909	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. Journal of Musculoskeletal Neuronal Interactions, 2019, 19, 253-257.	0.1	0
910	P-220: Use of Carfilzomib regimens in patients with Multiple Myeloma refractory to CD38 antibodies: a subgroup analysis from a prospective observational study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S160-S161.	0.2	0
911	P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S104.	0.2	0
912	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Blood, 2021, 138, 4202-4202.	0.6	0
913	Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine. Blood, 2021, 138, 3802-3802.	0.6	0
914	Single Cell Analysis of MYD88 L265P and MYD88 WT WaldenstrÃ¶m Macroglobulinemia Patients. Blood, 2021, 138, 1599-1599.	0.6	0
915	Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy. Blood, 2021, 138, 3799-3799.	0.6	0
916	Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination. Blood, 2021, 138, 3791-3791.	0.6	0
917	Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study. Blood, 2021, 138, 1672-1672.	0.6	0
918	Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study. Blood, 2021, 138, 3207-3207.	0.6	0

#	Article	IF	Citations
919	Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic. Blood, 2021, 138, 1657-1657.	0.6	0
920	Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients. Blood, 2021, 138, 3752-3752.	0.6	0
921	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. Blood, 2020, 136, 12-12.	0.6	0
922	Characterization and clinical implications of peripheral arterial involvement in transthyretin cardiac amyloidosis cardiomyopathy. European Heart Journal, 2020, 41, .	1.0	0
923	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. Blood, 2020, 136, 8-8.	0.6	0
924	Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. Blood, 2020, 136, 19-20.	0.6	0
925	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. Blood, 2020, 136, 29-29.	0.6	0
926	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood, 2020, 136, 6-7.	0.6	0
927	Investigating the impact of aging and hyperlipidaemia on metformin cardioprotection against carfilzomib-induced cardiotoxicity in vivo. European Heart Journal, 2020, 41, .	1.0	0
928	Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study. Blood, 2020, 136, 33-35.	0.6	0
929	Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study. Blood, 2020, 136, 9-10.	0.6	0
930	Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging. Blood, 2020, 136, 18-18.	0.6	0
931	Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid. Endokrynologia Polska, 2012, 63, 312-5.	0.3	0
932	Author's reply: To PMID 23705905. Expert Opinion on Pharmacotherapy, 2014, 15, 300.	0.9	0
933	The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. Hemato, 2022, 3, 204-218.	0.2	0